Theralase Technologies (TSXV:TLT) EV-to-Revenue : 52.77 (As of Jun. 05, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Theralase Technologies's enterprise value is C$43.32 Mil. Theralase Technologies's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.82 Mil. Therefore, Theralase Technologies's EV-to-Revenue for today is 52.77.

The historical rank and industry rank for Theralase Technologies's EV-to-Revenue or its related term are showing as below:

TSXV:TLT' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.84 Med: 25.84 Max: 118.25
Current: 50.85

During the past 13 years, the highest EV-to-Revenue of Theralase Technologies was 118.25. The lowest was 4.84. And the median was 25.84.

TSXV:TLT's EV-to-Revenue is ranked worse than
93.95% of 827 companies
in the Medical Devices & Instruments industry
Industry Median: 3.1 vs TSXV:TLT: 50.85

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-05), Theralase Technologies's stock price is C$0.18. Theralase Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was C$0.00. Therefore, Theralase Technologies's PS Ratio for today is 45.00.

Theralase Technologies EV-to-Revenue Historical Data

The historical data trend for Theralase Technologies's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies EV-to-Revenue Chart

Theralase Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

59.89

33.40

93.40

59.92

37.69

Theralase Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															59.92	51.58	63.26	37.69	-

Competitive Comparison of Theralase Technologies's EV-to-Revenue

For the Medical Devices subindustry, Theralase Technologies's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's EV-to-Revenue falls into.

Theralase Technologies EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Theralase Technologies's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	43.323	/	0.821
	=	52.77

Theralase Technologies's current Enterprise Value is C$43.32 Mil.
Theralase Technologies's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.82 Mil.

Theralase Technologies (TSXV:TLT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Theralase Technologies's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.18	/	0.004
	=	45.00

Theralase Technologies's share price for today is C$0.18.
Theralase Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00.

Theralase Technologies EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Theralase Technologies (TSXV:TLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

TLTFF:USA

Address

41 Hollinger Road, Toronto, ON, CAN, M4B 3G4

Website

https://www.theralase.com

Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.

Executives

Matthew Thomas Perraton

Director